EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

• Status: Not yet recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpatient care (primary care, preventive cardiology, or general cardiology, depending on risk level).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Emergency Department (ED) patients with chest pain

• 40-75 years old

• a low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL on an ED lipid panel or have known diabetes or Atherosclerotic Cardiovascular Disease (ASCVD)

Exclusion Criteria:

• Subject unwilling to take study medication

• Pregnancy or breastfeeding

• Inability to take study medication or, in the opinion of the Investigators/subject's doctors unsuitable for study participation

• ST-Segment Elevation Myocardial Infarction (STEMI) Activation

• ST-Segment Depression >1 mm

• On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran)

• Unstable Vitals (Blood Pressure (BP) <90, Heart Rate (HR) >120 or <50, O2 sat <90%)

• Statin Intolerance

• High-sensitivity Troponin I ≥100 ng/L

• End-Stage Renal Disease (ESRD) and/or glomerular filtration rate (GFR) <30 mL/min/1.73 m2

• Liver Cirrhosis

• Hospitalization

• Life Expectancy <1 Year

• Transfer from Another Hospital

• Prisoner

• Non-English Speaking